valine has been researched along with Cardiac Failure in 210 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.48) | 18.7374 |
| 1990's | 13 (6.19) | 18.2507 |
| 2000's | 154 (73.33) | 29.6817 |
| 2010's | 39 (18.57) | 24.3611 |
| 2020's | 3 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Berry, JD; Coniglio, AC; de Lemos, JA; Drazner, MH; Fox, ER; Garg, S; Grodin, JL; Hall, ME; Khan, SS; Loungani, RS; Mentz, RJ; Pandey, A; Savla, JJ; Segar, MW; Shah, A; Shah, S | 1 |
| Boeckel, JN; Bordalo, DM; Drewe-Boss, P; Eger, N; Gaul, S; Ghanbari, M; Gotthardt, M; Haas, J; Katus, HA; Kneuer, JM; Kokot, KE; Lai, A; Laufs, U; Liss, M; Meder, B; Möbius-Winkler, M; Müller, M; Ohler, U; Rebs, S; Schoppe, L; Streckfuss-Bömeke, K; Tappu, R | 1 |
| Bensch, J; Bunch, TJ; Fang, JC; Greene, T; Hess, R; Lyons, A; Piccini, JP; Siu, A; Spertus, JA; Stehlik, J; Steinberg, BA; Wohlfahrt, P; Zhang, M | 1 |
| Fang, S; He, H; Hua, Y; Huang, Y; Li, R; Liang, S; Liu, P; Tian, Y; Xu, F; Yang, X; Yuan, Y; Zhang, Z | 1 |
| Shi, KH; Tao, H; Yang, JJ | 1 |
| Dorhout, B; van der Meer, P; Voors, AA | 1 |
| Cohn, JN; Gimpelewicz, C; Hua, TA; Kandra, A; Krum, H; Latini, R; Lesogor, A; Massie, B; Tognoni, G; Zalewski, A | 1 |
| Backman, SB; Bui, H; Hatzakorzian, R; Schricker, T | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Claggett, B; Gupta, DK; Kraigher-Krainer, E; Lefkowitz, MP; McMurray, JJ; Packer, M; Pieske, B; Santos, A; Shah, AM; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Anand, IS; Cohn, JN; Kuskowski, M; Rector, TS; Snider, J | 1 |
| Bransford, T; Claggett, B; Jhund, PS; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM | 1 |
| Claggett, BL; Jhund, PS; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, BM; Prescott, MF; Shah, AM; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Bramlage, P; Ferrero, C; Gomez, T; Minguet, J; Sutton, G | 1 |
| İkitimur, B; Karadağ, B; Kılıçkıran Avcı, B; Öngen, Z | 1 |
| Morrow, T | 1 |
| Baumhäkel, M; Böhm, M; Müller, U | 1 |
| Fu, L; Gao, Y; Han, Y; Li, Y; Ma, D; Shen, J; Wang, F; Wang, Y; Xie, R; Zhou, P | 1 |
| Jiang, B; Liu, ZH; Qu, FZ | 1 |
| Baumhäkel, M; Müller, U | 1 |
| Capron, J; Steichen, O | 1 |
| Feldman, D; Wexler, R | 1 |
| Califf, RM; Maggioni, AP; McMurray, JJ; Moukarbel, GV; Pfeffer, MA; Scheiman, JM; Signorovitch, JE; Solomon, SD; Velazquez, EJ; White, HD | 1 |
| Andrews, CD; Brunel, P; MacDonald, TM; Parthasarathy, HK; Pieske, B; Struthers, AD; Weisskopf, M | 1 |
| Anand, IS; Bishu, K; Cohn, JN; Ishani, A; Kuskowski, MA; Rector, TS | 1 |
| Anand, IS; Cohn, JN; Holwerda, NJ; Kuskowski, M; Rector, TS; Thomas, S | 1 |
| Baba, HA; Boese, D; Christoph, DC; Erbel, R; Hunold, P; Johnson, KT; Philipp, S; Schlosser, TW | 1 |
| Bailey, J; Black, HR; Samuel, R; Zappe, D | 1 |
| Han, LH; Jiang, B; Jiang, WP; Li, HX; Liu, ZH; Qu, FZ; Zou, C | 1 |
| Iannazzo, S; Pradelli, L; Zaniolo, O | 1 |
| Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B | 1 |
| Bellocci, F; Crea, F; Giubilato, G; Ierardi, C; Pieroni, M; Santangeli, P; Vitulano, N | 1 |
| McMurray, JJ; Swedberg, K | 2 |
| Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Bernheim, A; Brunner-La Rocca, HP; Kiowski, W; Kuster, GM; Morgenthaler, NG; Mueller, B; Nietlispach, F; Rickli, H; Riesen, W; Rüter, F; Schindler, R; Schuetz, P | 1 |
| Belenkov, Y; Califf, RM; Finn, PV; Kenchaiah, S; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Shamshad, F; Soler-Soler, J; Solomon, SD; Swedberg, K; Varshavsky, S; Velazquez, EJ | 1 |
| Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH | 1 |
| Allhoff, T; Anand, IS; Cohn, JN; Drexler, H; Jantzen, F; Kempf, T; Kuskowski, M; Rector, TS; Tapken, H; Wollert, KC | 1 |
| Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E | 1 |
| Ruilope, LM; Segura, J | 1 |
| Anand, IS; Angelici, L; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Prescott, M; Solomon, S; Tognoni, G | 1 |
| Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M | 1 |
| Aparasu, RR; Ashton, CM; Chen, H; Desai, RJ; Deswal, A; Johnson, ML; Mehta, HB; Morgan, RO | 1 |
| Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E | 1 |
| Maksimov, ML; Mochkin, IA; Starodubtsev, AK | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Yui, Y | 1 |
| Joffe, MM; Yang, W | 1 |
| Bransford, T; Gong, J; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shah, A; Shi, V; Solomon, SD; Takeuchi, M; Voors, A; Zile, M | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Adourian, A; Anand, IS; Cohn, JN; Kuskowski, M; Muntendam, P; Rector, TS | 1 |
| Califf, RM; Giles, T; Haffner, SM; Hernandez, AF; Krum, H; Leiter, LA; Martinez, FA; Mazzone, T; McMurray, JJ; Rutten, GE; Standl, E; Sun, JL; Thomas, L; Tognoni, G; Wong, YW | 1 |
| Lee, TH | 1 |
| Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G | 1 |
| Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R | 1 |
| Barlera, S; Benza, RL; Chiang, YT; Cohn, JN; Gottlieb, SO; Kleemann, TD; Latini, R; Rosconi, F; Staszewsky, L; Vandervoort, PM; Volpi, A; Wong, M | 1 |
| Anand, I; Cohn, JN; Gottlieb, SO; Latini, R; Maggioni, AP; Tognoni, G | 1 |
| Greenberg, BH | 1 |
| Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H | 1 |
| Cohn, JN | 3 |
| Anand, I; Bevilacqua, M; Cardano, P; Chiang, YT; Cohn, JN; Dunselman, PH; Holwerda, NJ; Judd, D; Latini, R; Maggioni, AP; Masson, S; Salio, M; Tognoni, G | 1 |
| Hollenberg, NK | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Fisher, LD; Glazer, RD; Latini, R; Maggioni, AP; Masson, S; Tognoni, G | 1 |
| Komajda, M | 2 |
| Kohno, M | 1 |
| Kubota, T; Takeshita, A | 1 |
| Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Carson, P; Cohn, JN; Tognoni, G | 1 |
| Terra, SG | 1 |
| Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Hashimoto, R; Kawahara, S; Matsuzaki, M; Umemoto, S | 1 |
| Ghali, JK | 1 |
| Jermendy, G; Matos, L; Winkler, G | 1 |
| Bertocchi, F; Ceconi, C; De Tommasi, E; Ferrari, R; Francolini, G; Guida, P; Iacoviello, M; Massari, F; Pitzalis, MV; Rizzon, P; Romito, R | 1 |
| Vachiéry, JL | 1 |
| Deswal, A; Mann, DL | 1 |
| Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S | 1 |
| Latini, R; Maggioni, AP; Masson, S; Staszewsky, L | 1 |
| Goa, KL; Wellington, K | 1 |
| Doi, M; Kobayashi, S; Kohno, M; Matsuzaki, M; Oda, T; Ohkusa, T; Okuda, S; Tokuhisa, T; Yamamoto, T; Yano, M | 1 |
| Hukai, D; Ishii, C; Kanamori, T; Ohbayashi, Y; Ohnishi, M; Ohno, K; Okabayashi, T; Ozawa, T; Sakaguchi, T; Sichiri, G; Tanaka, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yokohama, H | 1 |
| Pfeffer, M | 1 |
| McAnulty, JH | 1 |
| Lai, KN; Lam, KY; Leung, JC; Li, PS; Wing-Hon Lai, K; Yu, CM | 1 |
| Liebson, PR | 1 |
| Schlosshan, D; Tan, LB; Williams, SG | 1 |
| Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H | 1 |
| Piña, IL | 1 |
| Crijns, HJ; Folkeringa, RJ; Pinto, YM | 1 |
| Aknay, N; Anand, I; Barlera, S; Cohn, JN; Glazer, R; Hester, A; Latini, R; Staszewsky, L; Wong, M | 1 |
| Angeli, F; Verdecchia, P | 1 |
| Califf, RM; Friedman, JY; Gnanasakthy, A; Reed, SD; Schulman, KA; Velazquez, EJ | 1 |
| Birkenhäger, WH; Staessen, JA | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Dahlöf, B; Kanae, K; Mochizuki, S; Shimizu, M; Tajima, N; Taniguchi, I; Yoshida, S | 1 |
| Nguyen, A; Sharma, S | 1 |
| Croom, KF; Keating, GM | 1 |
| Aknay, N; Carson, P; Chiang, YT; Cohn, JN; Farsang, C; Glazer, RD; Krum, H; Maggioni, AP | 1 |
| Aknay, N; Anand, I; Baruch, L; Cohn, JN; Glazer, RD; Hester, A; Heywood, JT; Krum, H; Vanhaecke, J | 1 |
| Ripley, TL | 1 |
| Aknay, N; Baruch, L; Feliciano, N; Goedel-Meinen, L; Hester, A; Hofmann, M; Majahalme, SK; Prescott, MF | 1 |
| Anand, I; Barlera, S; Carbonieri, E; Cohn, J; Gonzini, L; Latini, R; Maggioni, AP; Opasich, C; Tavazzi, L | 1 |
| Komuro, I; Kuwabara, Y | 1 |
| Erhardt, LR | 1 |
| Barlera, S; Carson, PE; Cerè, E; Cohn, JN; Glazer, R; Latini, R; Maggioni, AP; Masson, S; Singh, SN; Tognoni, G | 1 |
| Cohn, JN; Giardini, A; Glazer, R; Hester, A; Majani, G; Opasich, C; Tavazzi, L; Tognoni, G | 1 |
| Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Berry, GJ; Faul, JL; Vagelos, R; Walia, R; Weinkauf, J | 1 |
| Aknay, N; Anand, IS; Chiang, YT; Cohn, JN; Florea, VG; Glazer, RD; Hester, A; Kuskowski, MA; Latini, R; Maggioni, AP; Opasich, C; Rector, TS | 1 |
| Cerulli, A; Frech, FH; Smith, DG | 1 |
| Anand, IS; Cohn, JN; Florea, VG; Glazer, R; Hester, A; Kuskowski, MA; Latini, R; Masson, S; Mocarelli, P; Rector, T; Signorini, S | 1 |
| Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV | 1 |
| Barrios Alonso, V; Calderón Montero, A; Escobar Cervantes, C | 1 |
| McMurray, JJ | 2 |
| Temple, R | 1 |
| Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F | 1 |
| Liu, DS; Ye, JF | 1 |
| Drexler, H; Landmesser, U | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tan, LB; Tognoni, G; Vago, T; Wong, M | 1 |
| Kjeldsen, SE; Mistry, NB; Westheim, AS | 1 |
| Alexander, A; Buxbaum, J; Greenberg, B; Jacobson, DR; Kitzman, DW; Lavori, P; Tagoe, C; Thaneemit-Chen, S | 1 |
| Anand, I; Carretta, E; Cohn, J; Glazer, R; Ingrillì, F; Krum, H; Latini, R; Maggioni, AP; Masson, S; Pettinati, G; Tognoni, G | 1 |
| Battegay, E; Calvo-Vargas, C; Cieśliński, A; Degaute, JP; Holwerda, NJ; Hua, T; Julius, S; Kjeldsen, S; Kobalava, J; Laragh, JH; McInnes, GT; Pedersen, OL; Plat, F; Rudyatmoko, FP; Siamopoulos, KC; Störset, O; Weber, M; Zanchetti, A | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Skvortsov, AA; Sychev, AV | 2 |
| Anavekar, NS; Arnold, JM; Bourgoun, M; Ghali, JK; Køber, L; Pfeffer, MA; Skali, H; Solomon, SD; Thune, JJ; Velazquez, EJ | 1 |
| Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Ott, P | 1 |
| Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV | 1 |
| Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kondo, T; Li, L; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Ohno, T; Okada, H; Takemura, G | 1 |
| Dahlöf, B; Ikewaki, K; Kanae, K; Kawai, M; Mochizuki, S; Ogawa, K; Ohta, M; Okazaki, F; Seki, S; Shimizu, M; Tajima, N; Taniguchi, I; Taniguchi, M; Yamada, T; Yoshida, S; Yoshikawa, M | 1 |
| Mitsuyama, S | 2 |
| Akazawa, H; Komuro, I; Kudo, Y | 1 |
| Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Omvik, P; Rostrup, M | 1 |
| Bissessor, N; White, H | 1 |
| Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S | 1 |
| Deswal, A; Mann, DL; Ramasubbu, K | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M | 1 |
| Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ | 1 |
| Gaballa, MA; Goldman, S; Guarraia, D; Johnson, N; Thai, H | 1 |
| Havranek, EP | 1 |
| Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD | 1 |
| Burrell, LM; Johnston, CI | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Iannini, JP; Krombach, RS; Melton, DM; Mukherjee, R; O, SJ; Spinale, FG; Whitebread, S | 1 |
| Clair, MJ; Cox, MH; de Gasparo, M; Hebbar, L; Iannini, JP; Melton, DM; Mukherjee, R; Spinale, FG; Thomas, PB; Whitebread, S | 1 |
| Bolshakova, TD; Fomina, IG; Kazakov, EN; Lyusov, VA; Mazayev, VP; Olbinskaya, LI; Orlov, VA; Spormann, DO; Sulimov, VA; Sullivan, J; Zvereva, TV | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG; Whitebread, S; Zellner, JL | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Rios, G; Spinale, FG; Whitebread, S | 1 |
| Leary, AC; Lim, PO; MacDonald, TM; McMahon, AD; Shiels, P | 1 |
| Anand, I; Baruch, L; Cohen, IS; Cohn, JN; Judd, D; Ziesche, S | 1 |
| Kirk, JK | 1 |
| Cohn, JN; Glazer, RD; Hester, A; Spormann, D; Tognoni, G | 1 |
| Bohlender, J; Dietz, R; Haass, M; Höhnel, K; Luft, FC; Scheuermann, M; Thibault, G; Willenbrock, R | 1 |
| van Veldhuisen, DJ; Voors, AA | 1 |
| Coca, A; Giner, V | 1 |
| Califf, RM; Cohn, JN | 1 |
| Pfeffer, MA | 1 |
| Petkun, W | 1 |
| Cukon, S; Ennezat, PV; Hammer, A; Infeld, J; Jorde, UP; Le Jemtel, TH; Lisker, J; Sonnenblick, EH; Suryadevara, V | 1 |
| Bonarjee, VV; Dickstein, K | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG | 1 |
| Cohn, JN; Glazer, R; Spormann, D; Tognoni, G | 1 |
| Iwao, H; Izumi, Y; Kawano, H; Kim, S; Kimoto, M; Yoshiyama, M; Zhan, Y | 1 |
| Kulbertus, H | 1 |
| Thürmann, PA | 1 |
| Miller, AB; Srivastava, P | 1 |
| Hayashida, W; Yasaka, A | 1 |
| Fruhwald, FM; Kickenweiz, E; Klein, W; Zweiker, R | 1 |
| De Gasparo, M; Domergue, V; Fornes, P; Giudicelli, JF; Richer, C | 1 |
| Auer, JW; Berent, R; Eber, B | 1 |
| Ogihara, T; Rakugi, H | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| Cohn, JN; Tognoni, G | 1 |
| Piérard, L | 1 |
| Baicu, SC; deGasparo, M; Goldberg, AT; Hendrick, JW; Joffs, C; King, MK; Krombach, RS; Multani, MM; Sample, JA; Spinale, FG | 1 |
| Barlera, S; Höglund, C; Latini, R; Staszewsky, L; Volpi, A; Wong, M | 1 |
| Haddy, FJ | 1 |
| Cayley, WE | 1 |
| Forfar, JC; Munir, S | 1 |
| Campbell, DJ | 1 |
| Doszpod, J; Fekete, M; Gáti, I; Járai, I; Mestyán, J; Preisz, J; Soltész, G | 1 |
40 review(s) available for valine and Cardiac Failure
| Article | Year |
|---|---|
The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
LCZ696 : a new paradigm for the treatment of heart failure?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials, Phase II as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2015 |
Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan: more than a decade of experience.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Dual-acting angiotensin receptor-neprilysin inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Volume; Endopeptidases; Heart Failure; Humans; Hypertension; Neprilysin; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2011 |
[Application of AT1-angiotensin II receptor blocker valsartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Drug Monitoring; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renal Insufficiency; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Water-Electrolyte Balance | 2011 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2002 |
[Pharmacological treatment of heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Infusions, Intravenous; Pyridazines; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2003 |
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Failure; Humans; Hypertension; Japan; Losartan; Myocardial Infarction; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Complications; Heart Failure; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan for the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Valsartan: in chronic heart failure.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Agents; Drug Administration Schedule; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
VALUE: to the heart of the matter.
Topics: Antihypertensive Agents; Heart Failure; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan in chronic heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Drug Therapy, Combination; Female; Formularies, Hospital as Topic; Heart Failure; Humans; Liver Diseases; Male; Patient Education as Topic; Pregnancy; Randomized Controlled Trials as Topic; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2005 |
[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Indoles; Lisinopril; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Losartan; Systole; Tetrazoles; Valine; Valsartan | 2005 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Pacemaker, Artificial; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2005 |
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2006 |
Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Heart Failure; Humans; Long-Term Care; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
[Val-HeFT trial--evidence for valsartan in heart failure].
Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2007 |
[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Myocardial Infarction; Severity of Illness Index; Survival Rate; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Anti-angiotensin therapy: new perspectives.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Fumarates; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Imidazoles; Kidney Diseases; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1997 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
Cardiac protection: evolving role of angiotensin receptor blockers.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Middle Aged; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2000 |
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Prognosis; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
[Use of angiotensin II receptor blockaders in heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Heart Failure; Humans; Irbesartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2000 |
Valsartan: a novel angiotensin type 1 receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2001 |
[Angiotensin I receptor blockers for heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Benzimidazoles; Biphenyl Compounds; Contraindications; Cough; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2001 |
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
65 trial(s) available for valine and Cardiac Failure
| Article | Year |
|---|---|
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Echocardiography, Doppler, Color; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2014 |
Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Receptors, Cell Surface; Regression Analysis; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Heart Atria; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Troponin T; Valine; Valsartan | 2014 |
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Data Interpretation, Statistical; Diastole; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Outpatients; Practice Guidelines as Topic; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2008 |
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Exercise Tolerance; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Renin-Angiotensin System; Superoxide Dismutase; Tetrazoles; Valine; Valsartan | 2010 |
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Female; Follow-Up Studies; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Cystatin C; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Potassium; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biomarkers; Diabetic Angiopathies; Female; Growth Differentiation Factor 15; Heart Failure; Humans; Hypertension; Male; Middle Aged; Placebos; Prognosis; Regression Analysis; Risk Assessment; Risk Factors; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2010 |
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2011 |
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2012 |
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valine; Valsartan | 2012 |
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Galectin 3; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |
Safety and efficacy of valsartan versus enalapril in heart failure patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2002 |
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Survival Rate; Tetrazoles; Time; Valine; Valsartan | 2002 |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Biomarkers; Double-Blind Method; Follow-Up Studies; Heart Failure; Humans; Kinetics; Natriuretic Peptide, Brain; Norepinephrine; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2003 |
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Treatment Outcome; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Effect of Valsartan on hospitalization: results from Val-HeFT.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Lisinopril; Male; Middle Aged; Norepinephrine; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Coronary Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Double-Blind Method; Heart Failure; Hospitalization; Humans; Risk Factors; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2004 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2004 |
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
Topics: Antihypertensive Agents; Echocardiography; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Survival Analysis; Tetrazoles; United States; Valine; Valsartan; Ventricular Remodeling | 2004 |
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care Costs; Health Resources; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Ischemia; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2004 |
Heart attack patients with complications. Treat with valsartan, captopril, or both?
Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Quality of Life; Risk Factors; Single-Blind Method; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Neurotransmitter Agents; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left | 2004 |
Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Sex Distribution; Tetrazoles; United States; Valine; Valsartan | 2005 |
Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice.
Topics: Aged; Anemia; Antihypertensive Agents; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Prevalence; Prognosis; Prospective Studies; Registries; Risk; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Placebos; Quality of Life; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People | 2005 |
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Morbidity; Multivariate Analysis; Prevalence; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; C-Reactive Protein; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart; Heart Failure; Humans; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Observer Variation; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2006 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2005 |
Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
[Effects of benazepril combined with valsartan on congestive heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Female; Heart Arrest; Heart Failure; Humans; Hypertension; Male; Middle Aged; Proportional Hazards Models; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Follow-Up Studies; Heart Failure; Humans; Quinapril; Severity of Illness Index; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Quinapril; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Tetrazoles; Valine; Valsartan | 2007 |
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cause of Death; Confidence Intervals; Creatinine; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation; Male; Middle Aged; Norepinephrine; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Treatment Outcome; Troponin T; Valine; Valsartan | 2007 |
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction | 2008 |
Valsartan in heart failure patients previously untreated with an ACE inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Least-Squares Analysis; Lisinopril; Male; Matched-Pair Analysis; Middle Aged; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan | 1998 |
Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Cardiovascular Agents; Cross-Over Studies; Diastole; Double-Blind Method; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1999 |
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hormones; Humans; Lisinopril; Middle Aged; Single-Blind Method; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Sex Factors; Tetrazoles; Valine; Valsartan | 2000 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Probability; Quality of Life; Stroke Volume; Survival Analysis; Tetrazoles; Valine; Valsartan | 2001 |
Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT).
Topics: Angiotensin Receptor Antagonists; Double-Blind Method; Echocardiography; Heart Failure; Humans; Quality Assurance, Health Care; Quality Control; Reproducibility of Results; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
105 other study(ies) available for valine and Cardiac Failure
| Article | Year |
|---|---|
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.
Topics: Adult; Heart Failure; Humans; Isoleucine; Middle Aged; Prealbumin; Troponin I; Valine; Ventricular Remodeling | 2022 |
SLM2 Is A Novel Cardiac Splicing Factor Involved in Heart Failure due to Dilated Cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Connectin; Glutamates; Heart Failure; Humans; Lysine; Proline; RNA Splicing Factors; RNA-Binding Proteins; RNA, Messenger; Tropomyosin; Troponin I; Troponin T; Valine | 2022 |
Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program.
Topics: Aged; Atrial Fibrillation; Heart Failure; Humans; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Stroke Volume; Utah; Valine | 2022 |
Time Series Characteristics of Serum Branched-Chain Amino Acids for Early Diagnosis of Chronic Heart Failure.
Topics: Animals; Area Under Curve; Biomarkers; Disease Models, Animal; Disease Progression; Early Diagnosis; Heart Failure; Leucine; Machine Learning; Male; Metabolome; Metabolomics; Myocardial Infarction; Rats; Rats, Sprague-Dawley; ROC Curve; Valine | 2019 |
Galectin-3, new potential therapeutic target for cardiac remodelling.
Topics: Angiotensin II Type 1 Receptor Blockers; Female; Galectin 3; Heart Failure; Humans; Male; Tetrazoles; Valine | 2013 |
Broken heart syndrome triggered by an obstructive goiter not associated with thyrotoxicosis.
Topics: Aged; Airway Obstruction; Echocardiography; Female; Goiter, Nodular; Goiter, Substernal; Heart Failure; Humans; Intra-Aortic Balloon Pumping; Janus Kinase 2; Mutation; Myeloproliferative Disorders; Phenylalanine; Respiratory Insufficiency; Takotsubo Cardiomyopathy; Tracheal Stenosis; Valine | 2013 |
Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Denmark; Female; Heart Failure; Humans; Insurance, Health, Reimbursement; Losartan; Male; Tetrazoles; Valine; Valsartan | 2014 |
New Drug Entresto for Heart Failure Drums Up a Lot of Enthusiasm.
Topics: Angiotensin Receptor Antagonists; Drug Approval; Drug Combinations; Drug Costs; Heart Failure; Humans; Managed Care Programs; Neprilysin; Tetrazoles; Valine; Valsartan | 2015 |
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Cardiomegaly; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Expression Regulation; Heart; Heart Failure; Myocardial Infarction; Myocardium; Rats; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
[Effects of valsartan on sarcoplasmic reticulum calcium adenosine triphosphatase, protein kinase A and protein phosphatase 1 alpha in a rabbit model of heart failure].
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; Female; Heart Failure; Male; Protein Phosphatase 1; Rabbits; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Valine; Valsartan | 2008 |
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Multicenter Studies as Topic; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan | 2008 |
Disseminated zoster in an elderly patient.
Topics: Acyclovir; Aged, 80 and over; Antiviral Agents; Back; Face; Female; Heart Failure; Herpes Zoster; Herpesvirus 3, Human; Humans; Hypertension; Polymerase Chain Reaction; Valacyclovir; Valine | 2009 |
Combination of ARB and ACE inhibitors in heart failure patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2009 |
Heart failure and cardiac involvement as isolated manifestation of familial form of transthyretin amyloidosis resulting from Val30Met mutation with no clinical signs of polyneuropathy.
Topics: Amyloidosis, Familial; Cardiomyopathies; Echocardiography; Heart Failure; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Methionine; Microscopy, Electron; Middle Aged; Mutation; Prealbumin; Valine | 2009 |
[Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Female; Heart Failure; Male; Myocardium; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Topics: Age Factors; Aged; Antihypertensive Agents; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Female; Heart Failure; Hospital Costs; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Statistical; Quality of Life; Quality-Adjusted Life Years; Sex Factors; Tetrazoles; Valine; Valsartan | 2009 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Continuous Positive Airway Pressure; Coronary Artery Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Propanolamines; Radiography; Sleep Apnea, Obstructive; Tachycardia, Ventricular; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Premature Complexes | 2013 |
HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording | 2010 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension | 2012 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confounding Factors, Epidemiologic; Electronic Health Records; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Losartan; Male; Models, Structural; Proportional Hazards Models; Retrospective Studies; Risk; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan | 2012 |
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2011 |
Concerns about the Jikei Heart Study.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Endpoint Determination; Female; Heart Failure; Humans; Hypertension; Male; Tetrazoles; Valine | 2012 |
Subtle issues in model specification and estimation of marginal structural models.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Tetrazoles; Valine; Valsartan | 2012 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that w
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cough; Heart Failure; Humans; Lisinopril; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
[Therapy of heart failure. 2 neurohormone blockers are enough].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Angiotensin receptor blockers in heart failure: a work in progress.
Topics: Angiotensin II; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Progression; Echocardiography; Enzyme Activation; Heart Failure; Hypertension; Male; Myocardium; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-epsilon; Protein Transport; Rats; Rats, Inbred Dahl; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
BP drug approved for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Approval; Heart Failure; Humans; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2002 |
[Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Heart Failure; Humans; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Treatment Outcome; United States; United States Food and Drug Administration; Valine; Valsartan | 2002 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Evaluation Studies as Topic; Heart Failure; Humans; Incidence; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Are angiotensin II receptor antagonists indicated in chronic heart failure?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Effect of valsartan on hospitalization in Val-HeFT.
Topics: Heart Failure; Humans; Length of Stay; Patient Readmission; Prognosis; Tetrazoles; Valine; Valsartan | 2003 |
[ACE inhibitors and/or sartans in heart failure: is there a difference?].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Losartan; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dobutamine; Dogs; Drug Evaluation, Preclinical; Heart Failure; Myocardial Contraction; Norepinephrine; Phosphorylation; Protein Processing, Post-Translational; Receptors, Adrenergic, beta; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Tachycardia, Ventricular; Tacrolimus Binding Proteins; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2004 |
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[New options against undertreatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Losartan; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Implications of recent clinical trials for heart failure performance measures.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Practice Guidelines as Topic; Quality of Health Care; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aquaporin 2; Aquaporins; Drug Therapy, Combination; Fosinopril; Gene Expression; Heart Failure; Kidney Cortex; Kidney Medulla; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2004 |
VALIANT and EUROPA.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan in acute myocardial infarction trial.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Heart Failure; Humans; Male; Myocardial Infarction; Tetrazoles; Valine; Ventricular Dysfunction, Left | 2004 |
Aldosterone levels after angiotensin receptor blocker treatment.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2004 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Aged; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
Lymphocytic myocarditis after lung transplantation.
Topics: Acyclovir; Adult; Antiviral Agents; Biopsy, Needle; Cystic Fibrosis; Female; Follow-Up Studies; Heart Failure; Humans; Immunohistochemistry; Infectious Mononucleosis; Lung Transplantation; Lymphocytes; Myocarditis; Risk Assessment; Severity of Illness Index; Treatment Outcome; Valacyclovir; Valine | 2005 |
Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Budgets; Cost-Benefit Analysis; Heart Failure; Hospitalization; Humans; Models, Economic; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
How FDA currently makes decisions on clinical studies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Diabetic Nephropathies; Evidence-Based Medicine; Heart Failure; Humans; Propanolamines; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2005 |
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Captopril; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Heart Failure; Humans; Hypokalemia; Hypotension; Losartan; Meta-Analysis as Topic; Myocardial Infarction; Renal Insufficiency; Tetrazoles; Valine | 2005 |
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Disease Progression; Echocardiography; Heart Failure; Heart Ventricles; Humans; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke Volume; Survival Rate; Tetrazoles; Valine; Valsartan | 2006 |
[Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Long-Term Care; Myocardial Infarction; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Transthyretin V122I in African Americans with congestive heart failure.
Topics: Black or African American; Gene Frequency; Heart Failure; Heterozygote; Humans; Isoleucine; Mutation; Prealbumin; Valine | 2006 |
[Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family Practice; Germany; Heart Failure; Humans; Hypertension; Myocardial Infarction; Product Surveillance, Postmarketing; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Topics: Aged; Antihypertensive Agents; C-Reactive Protein; Cholesterol; Chronic Disease; Creatinine; Databases, Factual; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; Prognosis; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
Topics: Aged; Antihypertensive Agents; Comorbidity; Echocardiography; Female; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Prevalence; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Left bundle branch block is not good for your heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; British Columbia; Drug Prescriptions; Female; Heart Failure; Hospital Information Systems; Humans; Irbesartan; Losartan; Male; Ontario; Proportional Hazards Models; Quebec; Retrospective Studies; Survival Analysis; Survival Rate; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Blotting, Western; Creatinine; Disease Models, Animal; DNA; Heart Failure; Immunohistochemistry; Kidney Failure, Chronic; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nephrectomy; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2007 |
[Convincing results from the JIKEI Study].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Controlled Clinical Trials as Topic; Coronary Disease; Heart Failure; Humans; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
[New effective dosage of valsartan. High dosage--effective against high blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Prognosis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Blood Pressure; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Myocardial Infarction; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2007 |
From black and white to shades of gray: race and renin-angiotensin system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Diastole; Disease Models, Animal; Endothelins; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Pulmonary Artery; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Calcium Channels; Calcium Channels, L-Type; Calcium-Binding Proteins; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cell Membrane; Cells, Cultured; Dihydropyridines; Heart Failure; Myocardial Contraction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Sarcoplasmic Reticulum; Sodium-Potassium-Exchanging ATPase; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiac Pacing, Artificial; Endothelins; Epinephrine; Heart Failure; Hemodynamics; Male; Norepinephrine; Physical Exertion; Regional Blood Flow; Renin; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1998 |
AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; Exercise Test; Heart Failure; Hemodynamics; Male; Regional Blood Flow; Swine; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1998 |
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Reference Values; Research Design; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Quality of Life; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Diuresis; Heart Failure; Male; Myocardium; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Statistics, Nonparametric; Tetrazoles; Valine; Valsartan | 1999 |
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Losartan; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
AT1-receptor blockers.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Tetrazoles; Valine; Valsartan | 2000 |
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Fosinopril; Heart Failure; Humans; Lisinopril; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Treatment Failure; Valine; Valsartan | 2000 |
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2000 |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Catecholamines; Collagen; Diastole; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin-1; Gene Expression; Heart Failure; Heart Function Tests; Hydroxyproline; Myocardium; Myosin Heavy Chains; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Angiotensin; RNA, Messenger; Sodium Chloride, Dietary; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
[AT1-blocker in heart failure. Patients are readmitted more infrequently to the clinic].
Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
[Info-congress. COPERNICUS and Val-HEFT studies].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coronary Disease; Heart Failure; Humans; Propanolamines; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Valine; Valsartan | 2000 |
[Heart failure. With the AT1-blocker less frequent rehospitalization].
Topics: Angiotensin Receptor Antagonists; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
Alterations of load-induced p38 MAP kinase activation in failing rat hearts.
Topics: Animals; Antihypertensive Agents; Body Weight; Diastole; Enzyme Activation; Heart; Heart Failure; Hemodynamics; In Vitro Techniques; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; Organ Size; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Inbred Dahl; Reference Values; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Weight-Bearing | 2001 |
Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Heart Failure; Male; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin II type 1 receptor blockers and congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Receptor, Angiotensin, Type 1; Sample Size; Selection Bias; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
Are angiotensin II receptor blockers indicated in chronic heart failure?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
[Heart failure. Who benefits from an AT1 blocker?].
Topics: Angiotensin Receptor Antagonists; Clinical Trials as Topic; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
[ESC guidelines for therapy of heart failure. AT1 blockers are now also included].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Heart Failure; Humans; Practice Guidelines as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Spironolactone; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2002 |
Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Heart Failure; Male; Myocardium; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Swine; Tetrazoles; Valine; Valsartan | 2001 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Hypotension; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Risk; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
The postnatal changes in the circulating free amino acid pool in the newborn infant. 3. The plasma amino acid ratio in infants born after pregnancies complicated by toxaemia, placental infarction, impaired umbilical circulation and chronic maternal diseas
Topics: Amino Acids; Chronic Disease; Female; Glutamine; Glycine; Heart Defects, Congenital; Heart Failure; Humans; Infant, Newborn; Infarction; Isoleucine; Leucine; Maternal-Fetal Exchange; Methionine; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Cardiovascular; Pyelonephritis; Serine; Taurine; Torsion Abnormality; Umbilical Cord; Valine | 1971 |